Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2024-10-17 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
Regulatory Filings Classification · 1% confidence The document is a press release dated October 17, 2024, providing an update on the regulatory status of masitinib with the European Medicines Agency (EMA) and Health Canada. It details a negative opinion from the CHMP regarding conditional marketing authorization for ALS treatment. This type of announcement, focusing on regulatory decisions, clinical trial updates, and strategic next steps following regulatory feedback, is characteristic of an update intended for investors and the market regarding product development and regulatory progress. It is not a full annual report (10-K), a quarterly report (IR), a formal audit report (AR), or a transcript (CT). Since it is a specific update on drug development and regulatory outcomes, it fits best under the general category of Investor Relations material, but given the specific nature of regulatory feedback, it is most closely aligned with an announcement that might accompany or precede a more formal filing, or simply an important corporate update. Since there is no specific code for 'Regulatory Update' or 'Clinical Trial Update', and it is not a formal financial report, it falls under the general category of Regulatory Filings (RNS) as a miscellaneous, time-sensitive corporate announcement, or potentially an Investor Presentation (IP) if it were a slide deck, but here it reads like a press release. Given the options, RNS serves as the best general regulatory/corporate announcement fallback for non-standard filings that aren't explicitly financial reports or management changes. However, because it is a detailed update on the status of a key product's regulatory pathway, it is a significant piece of investor information. Given the options, RNS is the most appropriate catch-all for this type of regulatory news release that isn't a formal financial statement.
2024-10-17 English
Rapport financier semestriel 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2024' (Half-Year Financial Report as of June 30, 2024) for AB Science. It contains a detailed management report, consolidated financial statements, a declaration by the responsible officer, and an audit report. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. H1 2024
2024-10-10 French
Rapport financier semestriel 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2024' (Half-Year Financial Report as of June 30, 2024) for AB Science S.A. It contains a detailed summary, management discussion on financial situation, consolidated financial statements, and the auditor's report for the interim period. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. H1 2024
2024-10-10 French
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
Earnings Release Classification · 1% confidence The document is explicitly titled "AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD" and contains a section titled "CONSOLIDATED FINANCIAL ELEMENTS FOR THE FIRST HALF OF 2024". It details operating deficit, cash position, and R&D expenses for the first half of 2024 (ending June 30, 2024). This structure—a press release summarizing financial performance for a period shorter than a full year—is characteristic of an Interim/Quarterly Report (IR). While it contains clinical updates, the primary focus and announcement structure revolve around the half-year financial figures. H1 2024
2024-10-10 English
AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" and explicitly states it presents "RÉSULTATS FINANCIERS AU PREMIER SEMESTRE 2024" (Financial Results for the First Half of 2024). It details clinical development updates, financial situation (deficit, cash position), and key events related to drug trials (Masitinib, AB8939). This structure—a press release summarizing period-specific financial performance and operational highlights—is characteristic of an Earnings Release (ER). Although it contains detailed financial figures, it is presented as a summary announcement (a press release) rather than the comprehensive, formal regulatory filing (like a 10-K or a full Interim Report (IR)). Given the focus on summarizing the first half results, 'ER' is the most appropriate classification, distinguishing it from a full 'IR' which is typically a more structured, regulatory filing. H1 2024
2024-10-10 French
AB Science annonce avoir réalisé le règlement livraison de sa dernière augmentation de capital de 5,0 millions d’euros
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the completion ("règlement livraison") of a capital increase ("augmentation de capital") of 5.0 million Euros. It details the resulting changes in the share capital structure in a table format. This type of announcement, focusing on fundraising, financing activities, and the resulting capital structure change, directly aligns with the definition of 'Capital/Financing Update'. The code for this is CAP.
2024-10-09 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.